These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 8830951)

  • 21. Increased cortical inhibition in persons with schizophrenia treated with clozapine.
    Daskalakis ZJ; Christensen BK; Fitzgerald PB; Moller B; Fountain SI; Chen R
    J Psychopharmacol; 2008 Mar; 22(2):203-9. PubMed ID: 18308816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroleptic-resistant schizophrenia treated with clozapine and ECT.
    Benatov R; Sirota P; Megged S
    Convuls Ther; 1996 Jun; 12(2):117-21. PubMed ID: 8744173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR
    J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P50 sensory gating in adolescents from a pacific island isolate with elevated risk for schizophrenia.
    Myles-Worsley M; Ord L; Blailes F; Ngiralmau H; Freedman R
    Biol Psychiatry; 2004 Apr; 55(7):663-7. PubMed ID: 15038993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Atypical pharmacologic characteristics of an antipsychotic drug: clozapine].
    Gosselin O; Ribeyre JM; Kahn JP
    Encephale; 1997 Sep; 23 Spec No 4():2-6. PubMed ID: 9417400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Normalization of information processing deficits in schizophrenia with clozapine.
    Kumari V; Soni W; Sharma T
    Am J Psychiatry; 1999 Jul; 156(7):1046-51. PubMed ID: 10401450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of clozapine on aggression and substance abuse in schizophrenic patients.
    Volavka J
    J Clin Psychiatry; 1999; 60 Suppl 12():43-6. PubMed ID: 10372611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Creativity and antipsychotic drugs].
    Murry P; Torrecuadrada JL
    Encephale; 1997 Sep; 23 Spec No 4():17-9. PubMed ID: 9417399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.
    Raskin S; Katz G; Zislin Z; Knobler HY; Durst R
    Acta Psychiatr Scand; 2000 Apr; 101(4):334-6. PubMed ID: 10782556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study.
    Gross A; Joutsiniemi SL; Rimon R; Appelberg B
    Pharmacopsychiatry; 2004 May; 37(3):119-22. PubMed ID: 15138895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of phencyclidine on auditory gating in the rat hippocampus and the medial prefrontal cortex.
    Dissanayake DW; Zachariou M; Marsden CA; Mason R
    Brain Res; 2009 Nov; 1298():153-60. PubMed ID: 19699183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of clozapine and typical antipsychotic drugs on plasma 5-HT turnover and impulsivity in patients with schizophrenia: a cross-sectional study.
    Dursun SM; Szemis A; Andrews H; Whitaker P; Reveley MA
    J Psychiatry Neurosci; 2000 Sep; 25(4):347-52. PubMed ID: 11022399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human leukocyte antigen typing, response to neuroleptics, and clozapine-induced agranulocytosis in jewish Israeli schizophrenic patients.
    Meged S; Stein D; Sitrota P; Melamed Y; Elizur A; Shmuelian I; Gazit E
    Int Clin Psychopharmacol; 1999 Sep; 14(5):305-12. PubMed ID: 10529073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Memory impairment and auditory evoked potential gating deficit in schizophrenia.
    Hsieh MH; Liu K; Liu SK; Chiu MJ; Hwu HG; Chen AC
    Psychiatry Res; 2004 Feb; 130(2):161-9. PubMed ID: 15033186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia.
    Adler LE; Pachtman E; Franks RD; Pecevich M; Waldo MC; Freedman R
    Biol Psychiatry; 1982 Jun; 17(6):639-54. PubMed ID: 7104417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of clozapine response in schizophrenia.
    Pickar D; Owen RR; Litman RE; Hsiao JK; Su TP
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():129-32. PubMed ID: 7525541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P50 gating in deficit and nondeficit schizophrenia.
    Santos JL; Sánchez-Morla EM; Aparicio A; García-Jiménez MA; Villanueva C; Martínez-Vizcaíno V; Arango C
    Schizophr Res; 2010 Jun; 119(1-3):183-90. PubMed ID: 20153607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A machine learning approach using auditory odd-ball responses to investigate the effect of Clozapine therapy.
    Ravan M; Hasey G; Reilly JP; MacCrimmon D; Khodayari-Rostamabad A
    Clin Neurophysiol; 2015 Apr; 126(4):721-30. PubMed ID: 25213349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latency increase of auditory-evoked potential component N1 predicts poor neuroleptic response in schizophrenic patients.
    Adler G; Markert U; Gattaz WF
    Pharmacopsychiatry; 1994 Mar; 27(2):68-9. PubMed ID: 7913236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.